<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822898</url>
  </required_header>
  <id_info>
    <org_study_id>16/15/175</org_study_id>
    <nct_id>NCT02822898</nct_id>
  </id_info>
  <brief_title>Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults</brief_title>
  <acronym>MIHMoSA</acronym>
  <official_title>Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults, a Single-Blind Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prescription of intravenous maintenance solutions - although widespread - lacks important
      data on the optimal sodium and potassium content, which has given rise to an important debate
      in the scientific literature. Our study compares two different infusion fluids in 12 healthy
      adult volunteers without renal failure in a single-blind randomized crossover design over two
      48 hour periods during which subjects are not allowed to eat or drink. Fluid 1 is a premixed
      solution containing 54 mmol/L of sodium and 26 mmol/L of potassium; fluid 2 is sodium
      chloride 0.9% in glucose 5% with 40 mmol/L of potassium. Both solutions are administered at
      25 mL/kg of ideal body weight, as recommended by current guidelines (NICE 174) and both
      solutions are widely used in daily clinical practice. The primary hypothesis is that isotonic
      maintenance solutions lead to more fluid retention than hypotonic fluids. Metabolism of both
      solutions is assessed by sequential analysis of urine and serum, clinical parameters and
      bioelectrical impedance analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine Output</measure>
    <time_frame>48h</time_frame>
    <description>Urinary output over study period (as AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>48h</time_frame>
    <description>Body weight over study period (as AUC), used as a back up parameter for urinary output.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of sodium retention / excretion (excreted sodium / administered sodium)</measure>
    <time_frame>48h</time_frame>
    <description>Sodium retention / excretion over study period (mean at 24 and 48h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of hypokalemia (&lt;3.5 mmol/L), hyponatremia (&lt;135 mmol/L), hypernatremia (&gt;145 mmol/L)</measure>
    <time_frame>48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sodium level from its baseline value.</measure>
    <time_frame>48h</time_frame>
    <description>Area under the electrolyte concentration curve (baseline level is reference line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sodium and potassium level from its baseline value.</measure>
    <time_frame>48h</time_frame>
    <description>Area under the electrolyte concentration curve (baseline level is reference line)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Osmoregulatory Profile 1: urinary volume (mL)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean urinary volume (per fluid type) at T0-T12-T24-T36-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Osmoregulatory Profile 2: urinary osmolality (mOsm/kg)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean urinary osmolality (per fluid type). Urinary osmolality is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.</description>
  </other_outcome>
  <other_outcome>
    <measure>Osmoregulatory Profile 3: serum antidiuretic hormone (ADH) (pg/mL)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean serum ADH (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Osmoregulatory Profile 4: thirst score (scale 0-5)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean thirst score (per fluid type) at T0-T12-T24-T36-T48. The thirst score is a subjective score on a scale of 0-5.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume Regulatory Profile 1: urinary sodium (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean urinary sodium (per fluid type). Urinary sodium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. Urinary sodium is used to calculate the fractional excretion of sodium.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume Regulatory Profile 2: serum aldosterone (ng/dL)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean serum aldosterone (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume Regulatory Profile 3: urinary potassium (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean urinary potassium (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acid-Base Profile 1: serum chloride (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean serum chloride (per fluid type) at T0-T12-T24-T36-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acid-Base Profile 2: serum apparent strong ion difference (mEq/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean serum apparent strong ion difference (per fluid type) at T0-T12-T24-T36-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Acid-Base Profile 3: urinary anion gap (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean urinary anion gap (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Electrolytes Profile 1: Serum phosphate (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean serum phosphate (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Electrolytes Profile 2: Red blood cell magnesium (mmol/L)</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean red blood cell magnesium (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cortisol (Âµg/dL)</measure>
    <time_frame>48h</time_frame>
    <description>Serum cortisol as a measure of stress due to fasting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bioelectrical impedance analysis 1: Total body water</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean total body water (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bioelectrical impedance analysis : Extracellular volume</measure>
    <time_frame>48h</time_frame>
    <description>Sequential changes in mean extracellular volume (per fluid type) at T0-T24-T48.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Isotonic Maintenance Fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isotonic Maintenance Fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotonic Maintenance Fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypotonic Maintenance Fluid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% in Glucose 5% with 40mEq Potassium</intervention_name>
    <description>NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h</description>
    <arm_group_label>Isotonic Maintenance Fluid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucion 5%</intervention_name>
    <description>Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h</description>
    <arm_group_label>Hypotonic Maintenance Fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults, 18-70 years of age

          -  BMI 17-45 kg/mÂ².

          -  Creatinine clearance &gt;60 ml/min (according to eGFR CKD-EPI formula).

        Exclusion Criteria:

          -  Acute medical illness within 3 weeks of first study period

          -  Chronic medication: under diuretic therapy or other chronic medication that interfere
             with urine output or induce urine retention. All chronic medication should be declared
             before being enrolled in the study.

          -  Medical history:

               -  cardiac failure,

               -  malnourishment,

               -  diabetes mellitus,

               -  urological disease preventing spontaneous or complete emptying of the bladder,

          -  any medical or non-medical issue preventing complaint-free fasting for 48 hours (e.g.
             active peptic ulcer, psychosis, substance abuseâ¦)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Van Regenmortel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://guidance.nice.org.uk/CG174</url>
    <description>NICE guideline on Intravenous Fluid Therapy in Adults in Hospital</description>
  </link>
  <link>
    <url>http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf</url>
    <description>GIFTASUP guidelines</description>
  </link>
  <reference>
    <citation>Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised controlled trial. Lancet. 2002 May 25;359(9320):1812-8.</citation>
    <PMID>12044376</PMID>
  </reference>
  <reference>
    <citation>Moritz ML, Ayus JC. Maintenance Intravenous Fluids in Acutely Ill Patients. N Engl J Med. 2015 Oct;373(14):1350-60. doi: 10.1056/NEJMra1412877. Review.</citation>
    <PMID>26422725</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>August 7, 2016</last_update_submitted>
  <last_update_submitted_qc>August 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Niels Van Regenmortel</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Maintenance</keyword>
  <keyword>Intravenous solutions</keyword>
  <keyword>Intravenous fluids</keyword>
  <keyword>Tonicity</keyword>
  <keyword>Potassium</keyword>
  <keyword>Sodium</keyword>
  <keyword>Fluid retention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

